Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018

Executive Summary

Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for Lilly and Janssen.

You may also be interested in...



Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down

The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.

Rhetoric Doesn't Square With Reality, Sanofi Drug Pricing Report Says

Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.

Lilly Says Volume Growth Strategy, Launches Working Despite Price Pressures

Trulicity, Taltz grew in the first quarter, but below analyst consensus estimates. Company points to price decreases as holding down growth.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel